InvestSMART

Neurotech International Limited (ASX:NTI)

ALERT: Price-sensitive ASX Announcement for NTI
Current share price for NTI : $0.017 0.001 (6.25%)+
Announcement
Release
4 Aug 2026 9:26AM
Price at Release
$0.016
Full Release
download
Summary
Neurotech International Limited (ASX: NTI) announced that it has secured approximately $4.5 million in funding commitments through a share placement. This funding, which involves the issuance of around 321.41 million new fully paid ordinary shares at $0.014 each, will support the company's Phase III clinical trial of NTI164, a treatment for Autism Spectrum Disorder (ASD). The placement was facilitated by Taylor Collison Limited and Canary Capital Pty Ltd as joint lead managers and involved both existing and new institutional investors. The funds will be used for the clinical trial, regulatory activities, and general corporate purposes. The successful capital raising is expected to provide the financial resources necessary for Neurotech to achieve key milestones in its NTI164 development program.
Key Points
  • Receipt of binding commitments for $4.5 million placement.
  • Placement involves issuance of approximately 321.41 million new shares.
  • Shares priced at $0.014 each.
  • Funds to support Phase III trial of NTI164 for ASD.
  • Placement managed by Taylor Collison Limited and Canary Capital Pty Ltd.
  • Funds raised from both existing and new institutional investors.
  • Expected to fully fund the clinical trial to topline data readout.
  • Neurotech aims to address unmet needs in ASD treatment.
  • Announced by CEO Dr. Anthony Filippis.
  • Prospects for regulatory approval and commercialisation of NTI164.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.